Yes, a statin should be offered to a patient with a 5.4% 10-year ASCVD risk.
At least a moderate-intensity statin is recommended for adults at intermediate (5% to <10%) 10-year ASCVD risk to achieve ≥30% to 49% LDL-C reduction and reduce ASCVD risk. 1
Risk Category Classification
A 10-year ASCVD risk of 5.4% places this patient in the intermediate risk category (5% to <10%), according to the 2026 ACC/AHA Dyslipidemia Guidelines. This is a Class 1 (strong) recommendation with Level A (high-quality) evidence 1.
Treatment Approach
Statin Intensity Selection
- Start with at least moderate-intensity statin therapy (30-49% LDL-C reduction)
- For patients in the higher end of this risk range (closer to 10%), a high-intensity statin is beneficial to achieve ≥50% LDL-C reduction 1
Since your patient is at 5.4%, you're in the lower-middle portion of the intermediate range, making moderate-intensity statin the appropriate starting point.
Treatment Goals
Once statin therapy is initiated, it is reasonable to treat to a goal of LDL-C <100 mg/dL and non-HDL-C <130 mg/dL to reduce ASCVD risk 1. This is a Class 2a recommendation with Level B evidence.
Clinical Context and Nuances
Strength of Evidence
The 2026 guidelines represent the most current evidence-based approach, superseding the 2019 guidelines 2. The Class 1 recommendation for intermediate-risk patients reflects strong evidence from multiple large-scale randomized controlled trials demonstrating ASCVD risk reduction with statin therapy 1.
Risk Enhancement Considerations
Before initiating therapy, consider:
- Risk-enhancing factors that may strengthen the indication: family history of premature ASCVD, metabolic syndrome, chronic kidney disease, inflammatory disorders, elevated high-sensitivity CRP, hypertriglyceridemia 3
- Coronary artery calcium (CAC) scoring can refine treatment decisions if uncertainty exists. If CAC >0, particularly ≥100 AU or ≥75th percentile, this strengthens the statin indication 1, 4
Benefit-Risk Discussion
Always provide health behavior recommendations (diet, exercise, smoking cessation) in addition to discussing statin therapy 1. The benefit-risk profile strongly favors treatment at this risk level:
- Research shows statin therapy reduces ASCVD risk by 16-30% in adherent patients across various risk categories 5
- The 5-year number needed to treat (NNT) for intermediate-risk patients is approximately 75-204, which is clinically meaningful 5
Common Pitfalls to Avoid
- Don't defer treatment waiting for "higher risk" - The intermediate risk category has a Class 1 recommendation, meaning the benefit clearly outweighs risk
- Don't confuse borderline (3-5%) with intermediate (5-10%) risk - At 5.4%, this patient is definitively in the intermediate category where statins are recommended, not just "reasonable to consider"
- Don't ignore the 30-year risk in younger patients (30-59 years) - If your patient is in this age range, calculate 30-year risk as well, as ≥10% 30-year risk may further support treatment 1
Practical Implementation
- Initiate moderate-intensity statin (e.g., atorvastatin 10-20 mg, rosuvastatin 5-10 mg, or simvastatin 20-40 mg daily)
- Recheck lipid panel in 4-12 weeks to assess response
- Aim for LDL-C <100 mg/dL and non-HDL-C <130 mg/dL
- Monitor for statin-associated symptoms and adjust as needed
- Reinforce lifestyle modifications as foundational therapy
The evidence unequivocally supports statin therapy at this risk level to reduce cardiovascular morbidity and mortality.